Background. Despite the widespread use of opioids for the treatment of cancer pain, results from several surveys consistently show that pain is still prevalent in some patients with malignant diseases. The purinergic P2Y12 receptor is a primary site leading to microglial activation and hyperalgesic pain behaviors and is considered a key regulator in the prevention of the aggravation of clinical pain conditions. Genetic variability in the P2RY12 gene may contribute to individual differences in pain and opioid sensitivity.
Background. Despite the widespread use of opioids for the treatment of cancer pain, results from several surveys consistently show that pain is still prevalent in some patients with malignant diseases. The purinergic P2Y12 receptor is a primary site leading to microglial activation and hyperalgesic pain behaviors and is considered a key regulator in the prevention of the aggravation of clinical pain conditions. Genetic variability in the P2RY12 gene may contribute to individual differences in pain and opioid sensitivity.
Methods. We genotyped 31 single nucleotide polymorphisms (SNPs) throughout the P2RY12 gene and compared genotypes against pain measurements and opioid requirements in Japanese cancer pain patients (N 5 90). The most promising SNP association with pain severity was validated by genotyping an additional postoperative pain patient cohort (N 5 355).
Introduction
Pain is one of the most frequent symptoms among cancer patients in the terminal period, and the distress experienced by cancer pain patients causes anxiety, depression, and changes in social functions. Indeed, not only physical functions but also social functions and roles were found to be lower in cancer pain patients than in the general population; as a result, their global health and quality of life (QOL) was impaired severely [1] . The prevailing principle for cancer pain treatment is the World Health Organization (WHO) three-step analgesic ladder in which pain treatment is escalated from the use of nonopioids in the first step, through the second step that uses weak opioids for mild to moderate pain, up to the third step that applies strong opioids for moderate and severe pain [2] . According to this treatment strategy, pain reduction results in a significant improvement in QOL [3] . On the other hand, despite the widespread use and recognition of recommendations for the treatment of cancer pain, results from several surveys have consistently shown that pain is still prevalent in patients with malignant diseases [4] . In both neuropathic and inflammatory pain conditions, spinal sensitization is closely linked with pathological pain refractory to a variety of pharmacotherapies. An emerging concept states that immune cells (e.g., microglia) and neurons form an integrated network in which activation of an immune response modulates the excitability of nociception pathways, both in the periphery and in the central nervous system. Within the nervous system, neurons are surrounded by glia, especially microglia, which continuously monitor the extracellular environment and exchange information with one another as well as with neurons. In this manner, they profoundly modulate neuronal firing and can lead to hypersensitive pain behaviors [5] .
Microglia are activated massively when physiological homeostasis is threatened by factors including inflammation and nerve injury, setting a precedent for hypersensitive pain behaviors. Some aspects of the microglial response to injury can be mimicked by injection of ATP or attenuated by broad-spectrum inhibitors of purinergic signaling [6] . Microglia express an array of purinergic receptors that have been proposed to have important roles in the activation, chemotaxis, process extension, and paracrine signaling of these cells [7] . In particular, P2Y12 receptor expression is robust in the "resting" state but is dramatically reduced after microglial activation. It has been proposed that the P2Y12 receptor is a primary site at which nucleotides act to induce microglial chemotaxis during the initial stage of the response to threatened homeostasis in the nervous system [8] . Therefore, the P2Y12 receptor is considered one of the possible key regulators in the prevention of aggravation of clinical pain conditions. Genetic and environmental factors appear to influence individual differences in pain sensitivity and severity. With regards to genetic factors, various polymorphisms have been reported, including variations in the OPRM1 gene, which encodes the mu-opioid receptor, and variations in the GIRK2 gene, which encodes a subunit of G-proteinactivated inwardly rectifying potassium channels [9, 10] . However, to our knowledge, there are few reports on the intimate relationship between the P2Y12 receptor gene and clinical pain conditions, although several purinergic receptors have been shown to be related to psychiatric conditions (e.g., polymorphism of the P2X7 receptor gene is related to bipolar affective disorder) [11] . We hypothesized that polymorphism of the P2Y12 receptor gene contributes to individual differences in pain severity and tested this hypothesis in Japanese patients with cancer pain and postoperative pain.
Methods

Experiment 1
Participants
This study was approved by the appropriate institutional review boards in the respective hospitals involved, and written informed consent was obtained from all subjects. The inclusion criteria were 1) diagnosis of cancer pain (irrespective of the original organ and pathology of malignant lesions); 2) mean pain intensity in the past week higher than 3 on an 11-point numerical rating scale (NRS; 0 ¼ no pain, 10 ¼ worst possible pain); 3) pain duration greater than one week (recorded at inclusion); and 4) age older than 20 years. The exclusion criteria were 1) patients with slight or more severe cognitive dysfunction; 2) cancer patients with relevant brain metastasis; and 3) suspicion of an origin of pain other than cancer itself. Ninety patients (age ¼ 58.4 6 13.4 years; female, 50; pain duration ¼ 11.2 6 18.8 months) were enrolled in this study.
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In addition to pain intensity, we recorded total daily dosage of opioid analgesics based on weight (mean intravenous fentanyl equivalent dose [mg/kg À1 /day À1 ]) on the day of pain evaluation.
Genotyping Method
Venous blood samples were collected from all participants. Genomic DNA was isolated from peripheral blood lymphocytes using a standard salting-out method. Genomic DNA was whole-genome amplified, fragmented, denatured, and hybridized to a prepared Omni1-Quad BeadChip (Illumina, San Diego, CA, USA), which contained 1,140,419 markers. All 90 patients were genotyped using an Omni1-Quad BeadChip. Normalized bead intensity data obtained for each sample were loaded into GenomeStudio software (Genotyping module v. 1.8.4; Illumina), which converted fluorescence intensities into single nucleotide polymorphism (SNP) genotypes. We then used genotype data from whole-genome genotyping for the analysis of 31 SNPs within the P2RY12 gene region.
Statistical Analysis
We analyzed associations among genotypes, pain intensity, and opioid dosage using the Kruskal-Wallis (K-W) test and the Bonferroni test in 31 respective SNPs of the P2RY12 gene. The criterion for significance was set at a P value of less than 0.017 (0.05 before a priori Bonferroni correction). Linkage disequilibrium patterns of the relevant SNPs were plotted using Haploview [12] . In addition, the genotype of each of the screened SNPs was dichotomized into the major allele homozygote (TT) and a combination of the heterozygote and minor allele homozygote (TC þ CC). We compared the pain intensity and opioid dosage of these two groups using the Mann-Whitney (M-W) test. The criterion for significance was set at a P value of less than 0.05.
Experiment 2
To elucidate whether SNPs in the P2Y12 receptor gene influence pain intensity caused by other etiologies, we examined the relationship between genetic variations in the P2Y12 receptor gene, postoperative pain intensity, and opioid requirements. The details of the participants and methods are described elsewhere [13, 14] . Briefly, 355 patients (age ¼ 15-52 years; female, 230) who underwent cosmetic mandibular sagittal split ramus osteotomy participated in this study. In the postoperative period, their postoperative pain management was conducted by intravenous patient-controlled analgesia (PCA) with fentanyl. Total intraoperative fentanyl use and postoperative fentanyl use during the first 24 hours of the postoperative period were recorded, and the doses were normalized to patient body weight. The intensity of spontaneous pain was assessed three and 24 hours postoperatively using a 100 mm visual analog scale (VAS). The patients were genotyped using HumanHap300, HumanHap300-Duo, Human610-Quad v1, Human1M v1.0, and Human 1M-Duo v3 BeadChips. We analyzed the relationships between the relevant SNPs found in experiment 1 and three-and 24-hour postoperative pain intensity, as well as 24-hour postoperative opioid consumption. Linkage disequilibrium patterns of the relevant SNPs were plotted using Haploview [12] . For statistical analysis, SPSS 18.0J for Windows (International Business Machines Corporation, Armonk, NY, USA) was used. The Mann-Whitney test for two cohorts and the Kruskal-Wallis test for three cohorts were used to investigate the relationship between the SNPs and phenotype. Bonferroni correction was used if necessary to account for multiple comparisons. The criterion for significance was set at a P value of less than 0.05 for two cohorts and a P value of less than 0.017 for three cohorts (0.05 before a priori Bonferroni correction), respectively.
Results
Experiment 1
Five alleles of the P2RY12 gene SNPs (rs3732765, rs9859538, rs17283010, rs11713504, and rs10935840) demonstrated a significant difference in cancer pain severity (K-W test, P < 0.05) ( Table 1 ). These alleles of the P2RY12 gene SNPs represented one absolute linkage disequilibrium block of the P2RY12 gene (Figure 1) , and hence the patients were classified into three groups according to the genotype of the SNPs (i.e., major allele homozygosity, heterozygosity, or minor allele homozygosity). The patients with homozygosity for the minor alleles (N ¼ 3; female, 1; age¼ 57.7 6 2.5 years; pain NRS ¼ 9.3 6 1.2) demonstrated higher pain intensity compared with those with homozygosity for the major alleles (N ¼ 66; female, 36; age ¼ 59.9 6 12.8 years; pain NRS ¼ 5.4 6 1.8; P ¼ 0.0068) and those with heterozygosity for the minor alleles (N ¼ 21; female, 13; age ¼ 53.7 6 15.3 years; pain NRS ¼ 6.4 6 1.6; P ¼ 0.002) (Figure 2 ). The patients with homozygosity for the major alleles showed a comparably, but not significantly, lower pain intensity than those with heterozygosity for the minor alleles (P ¼ 0.02). Total daily dosages of opioid analgesics based on weight were comparable among the three patient groups (major allele homozygosity ¼ 3. (Figure 3 ). In addition, the association between the dichotomous genotypes of the five SNPs (TT, N ¼ 66; TC þ CC, N ¼ 24) and pain intensity reached significance (M-W test, P ¼ 0.0011) (Figure 2 ), although the opioid dosages of the groups were comparable (M-W test, P ¼ 0.69) (Figure 3 ).
Experiment 2
Of the five SNPs in the P2Y12 receptor gene that were found in experiment 1, the BeadChips used for genotyping included four (all except for rs11713504). We selected rs3732765 as the representative SNP among the four SNPs included because each SNP was found to be in almost absolute linkage disequilibrium with every other SNP. Linkage disequilibrium patterns were plotted using Haploview (Figure 4) [12] .
In the trichotomous analysis of each of the genotypes of the rs3732765 SNP, there was no significant relationship between three-hour postoperative pain intensity and genetic variation (K-W test, P ¼ 0.080) ( Table 2) . However, there were significant associations between 24-hour postoperative pain intensity and genetic variation in the trichotomous (K-W test, P ¼ 0.003) and dichotomous analyses (M-W test, P ¼ 0.003). Patients with homozygosity or heterozygosity for the minor T alleles demonstrated higher pain intensity in the 24-hour postoperative period compared with those with homozygosity for the major C alleles (Table 2) . Total 24-hour postoperative opioid consumptions based on weight were comparable (K-W test, P ¼ 0.612) ( Table 2) . 
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Discussion
The results of the present study showed that although patients with homozygosity for the minor alleles of the P2RY12 gene SNPs received relatively higher dosages of opioid analgesics, their cancer pain intensity was more severe than the other two patient groups. Further, the cancer pain severity of patients with heterozygosity for the minor alleles was located between the severities of the respective patient groups with homozygosity for the major and minor alleles. In other words, patients with major allele homozygosity demonstrated less pain intensity than those with heterozygosity and minor allele homozygosity. Another set of participants, who suffered from postoperative pain, followed a similar pattern. From our findings, it can be concluded that P2RY12 gene SNPs contribute to aggravation of inflammatory pain intensity.
The P2Y12 receptor on microglia is a primary site at which nucleotides act to induce microglial chemotaxis during the initial stage of the response to threatening states in the nervous system, leading to increased excitability of spinal dorsal horn neurons and the sensation of persistent pain. Once microglia are activated, neuronal-microglial communication maintains the neuronal hyperalgesic state and prolongs severe pain [15] . It has also been shown that purinergic agonists increase the excitability of afferent fibers and activate microglia in the nervous system, eliciting hypersensitive pain behaviors in naïve rats that mimic those observed in nerveinjured rats [16] . On the contrary, inhibition of the P2Y12 receptor by pharmacological blockade, antisense knockdown of P2Y12 receptor expression, or genetic deletion of the P2RY12 gene suppresses both mechanical allodynia and thermal hyperalgesia in nerve-injured rats [17] . The P2Y12 receptor is therefore considered one of the possible key regulators in the prevention of aggravation of clinical pain conditions. However, there are few reports on the intimate relationship between the P2Y12 receptor and clinical pain conditions. The minor alleles of P2RY12 SNPs (rs9859538, rs3732765, and so on) were revealed to be associated with cancer pain severity in the present study. This result indicates facilitation of the P2Y12 purinergic signaling pathway in patients with minor alleles of P2RY12 SNPs. Supporting evidence comes from a recent report on the association of P2Y12 receptor gene polymorphisms with platelet reactivity [18] . The minor allele of the P2RY12 SNP rs9859538 demonstrated a higher platelet reactivity, and the minor allele of the P2RY12 SNPs rs3732765 and others also demonstrated moderately higher platelet reactivity. These results suggest that signaling downstream from P2Y12 receptor activation is facilitated by these minor alleles of the P2RY12 SNPs. This is consistent with our present results. Currently, there are no relevant theories about the other three SNPs (rs17283010, rs11713504, and rs10935840) that were screened in our study.
In Japan, 174,269 SNPs have already been identified in the general population [19] . This database of common genetic variations in the Japanese general population contains 17 SNPs of the genes of some purinergic receptors that are plausibly associated with pain [19] . However, the SNPs of the P2Y12 receptor gene that were screened in the present study are still not included in the database. The total number of participants in our study was small, and there was a very limited number of patients with homozygosity for the minor alleles of the P2Y12 receptor gene SNPs. Such a limited number of participants increases the possibility of false positive results; hence, our results should be validated and confirmed in a larger-scale study with more participants. Nonetheless, the present study could demonstrate an association between genetic polymorphisms of the P2Y12 receptor gene and pain severity in patients with cancer pain and replicate this association in another set of patients with postoperative pain, indicating the clinical significance of the results. The P2RY12 gene and also P2RY13 and P2RY14 genes are all known to encode G i protein-coupled P2Y receptors, which are widely expressed in nociceptive neurons and inhibit nociceptive signaling [20] . Currently, the dosages of opioid analgesics that are appropriate for individual patients are identified only after time-consuming trial-and-error adjustments or titrations with multiple incremental doses. Time before achieving analgesia is of the essence for terminally ill cancer pain patients. If the minor alleles of the P2Y12 receptor gene are known in advance of starting treatment with analgesics, health care professionals might be able to predict potentially severe pain and determine appropriate dosages, thus achieving satisfactory analgesia promptly. Further, many physiological and pharmacological studies have succeeded in attenuation of neuropathic pain using a variety of molecules that target inhibition of microglial activation through suppression of various purinergic receptors, including not only P2Y12 but also P2X3, P2X4, and P2X7 on the microglial surface [21] . If the minor alleles of the P2Y12 receptor gene are known in advance, this might be very useful for predicting resistance to novel analgesics that specifically target inhibition of P2Y12 purinergic signaling. Genetic differences in pain signaling suggest opportunities to tailor pain management. Comprehensive analyses of genetic polymorphisms, including the SNPs of the P2Y12 receptor gene, would enable a more precise estimation of individual severity and conclusively improve the quality of pain treatment. 
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